Stoke rises on FDA's 'breakthrough therapy' tag for epileptic disorder drug

Stoke Therapeutics

04/12/2024 16:50

** Shares of Stoke Therapeutics  STOK.O  rise 12.6% to
$12.88 
    ** The biotech says it has received U.S. FDA's "breakthrough
therapy designation" for zorevunersen, its experimental drug for
epileptic disorder Dravet Syndrome
    ** The FDA's tag is meant to speed up development and review
of drugs to treat a serious condition or unmet medical need
    ** Breakthrough designation seems appropriate given disease
modifying potential in a field of symptomatic treatments,
brokerage BTIG says
    ** If approved, the drug could become the first disease
modifying treatment for the disease
    ** Including session's moves, stock up 143.54% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))